{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:57:56Z","timestamp":1788512276292,"version":"build-2803163510"},"reference-count":161,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.semradonc.2024.08.005","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T06:03:49Z","timestamp":1733983429000},"page":"110-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Breaking Down the Barriers for Patients With Cutaneous T-Cell Lymphoma: Current Controversies and Challenges for Radiation Oncologists in 2024"],"prefix":"10.1016","volume":"35","author":[{"given":"Belinda A.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Thursky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouthaina","family":"Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Specht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro V.","family":"Porceddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.semradonc.2024.08.005_bib0001","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0002","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3109\/10428194.2012.729831","article-title":"Incidence and survival patterns of cutaneous T-cell lymphomas in the United States","volume":"54","author":"Imam","year":"2013","journal-title":"Leukem Lymphom"},{"issue":"11","key":"10.1016\/j.semradonc.2024.08.005_bib0003","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jamaoncol.2022.3236","article-title":"Incidence trends of primary cutaneous T-Cell lymphoma in the US from 2000 to 2018: A SEER population data analysis","volume":"8","author":"Cai","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2024.08.005_bib0004","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2133.2008.08852.x","article-title":"Incidence of primary cutaneous T-cell lymphoma in Norway","volume":"160","author":"Saunes","year":"2009","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.semradonc.2024.08.005_bib0005","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.3390\/cancers12102921","article-title":"Epidemiology of cutaneous T-Cell lymphomas: A systematic review and meta-analysis of 16,953 patients","volume":"12","author":"Dobos","year":"2020","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.semradonc.2024.08.005_bib0006","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/cam4.472","article-title":"Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries","volume":"4","author":"Litvinov","year":"2015","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.semradonc.2024.08.005_bib0007","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1002\/cncr.29301","article-title":"Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries","volume":"121","author":"Litvinov","year":"2015","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.semradonc.2024.08.005_bib0008","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1002\/cncr.30758","article-title":"Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy","volume":"123","author":"Ghazawi","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0009","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.3390\/ijerph20043578","article-title":"Disparities in cutaneous T-Cell lymphoma incidence by race\/ethnicity and area-based socioeconomic status","volume":"20","author":"Wiese","year":"2023","journal-title":"Internat J Environ Res Public Health"},{"issue":"9","key":"10.1016\/j.semradonc.2024.08.005_bib0010","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s10552-021-01452-y","article-title":"Geographic clustering of cutaneous T-cell lymphoma in New Jersey: An exploratory analysis using residential histories","volume":"32","author":"Henry","year":"2021","journal-title":"Cancer Causes Control: CCC"},{"issue":"2","key":"10.1016\/j.semradonc.2024.08.005_bib0011","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1203475417745825","article-title":"Distribution and clustering of cutaneous T-Cell lymphoma (CTCL) cases in Canada during 1992 to 2010","volume":"22","author":"Ghazawi","year":"2018","journal-title":"J Cutan Med Surg"},{"issue":"10","key":"10.1016\/j.semradonc.2024.08.005_bib0012","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1111\/jdv.16325","article-title":"Mycosis fungoides: Developments in incidence, treatment and survival","volume":"34","author":"Kaufman","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"16","key":"10.1016\/j.semradonc.2024.08.005_bib0013","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semradonc.2024.08.005_bib0014","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.semradonc.2024.08.005_bib0015","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0016","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/ajd.12349","article-title":"Mycosis fungoides and S\u00e9zary syndrome: Current challenges in assessment, management and prognostic markers","volume":"57","author":"Hughes","year":"2016","journal-title":"Austral J Dermatol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0017","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40257-022-00732-w","article-title":"Real-life barriers to diagnosis of early mycosis fungoides: An international expert panel discussion","volume":"24","author":"Hodak","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.semradonc.2024.08.005_bib0018","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.17258","article-title":"The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients","volume":"181","author":"Scarisbrick","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0019","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13555-023-00895-2","article-title":"Healthcare provider experience in diagnosing and treating cutaneous T-Cell lymphoma","volume":"13","author":"Boh","year":"2023","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/archderm.136.4.497","article-title":"Group ToCCLP. accuracy, concordance, and reproducibility of histologic diagnosis in cutaneous T-Cell lymphoma: An EORTC cutaneous lymphoma project group study","volume":"136","author":"Santucci","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0021","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.semcancer.2023.06.004","article-title":"Artificial intelligence in digital pathology of cutaneous lymphomas: A review of the current state and future perspectives","volume":"94","author":"Doeleman","year":"2023","journal-title":"Sem Cancer Biol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0022","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jaci.2022.02.015","article-title":"T cells in the skin: Lymphoma and inflammatory skin disease","volume":"149","author":"Roediger","year":"2022","journal-title":"J Allerg Clin Immunol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0023","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijwd.2021.04.004","article-title":"A clinician's guide to cutaneous T-cell lymphoma presenting as recalcitrant eczematous dermatitis in adults","volume":"7","author":"Semaan","year":"2021","journal-title":"Int J Women's Dermatol"},{"issue":"2","key":"10.1016\/j.semradonc.2024.08.005_bib0024","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijwd.2016.11.006","article-title":"Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis","volume":"3","author":"Kelati","year":"2017","journal-title":"Int J Women's Dermatol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00000478-200001000-00005","article-title":"Efficacy of histologic criteria for diagnosing early mycosis fungoides: an EORTC cutaneous lymphoma study group investigation. European organization for research and treatment of cancer","volume":"24","author":"Santucci","year":"2000","journal-title":"Am JSurg Pathol"},{"issue":"308","key":"10.1016\/j.semradonc.2024.08.005_bib0026","first-page":"308ra158","article-title":"TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL","volume":"7","author":"Kirsch","year":"2015","journal-title":"Sci Translat Med"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0027","series-title":"Optimal Care Pathway for People with Cutaneous T-cell Lymphoma","year":"2023"},{"issue":"5","key":"10.1016\/j.semradonc.2024.08.005_bib0028","doi-asserted-by":"crossref","first-page":"522","DOI":"10.6004\/jnccn.2020.0022","article-title":"NCCN guidelines insights: Primary cutaneous lymphomas, version 2.2020: Featured updates to the NCCN guidelines","volume":"18","author":"Mehta-Shah","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0029","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1111\/ajd.13467","article-title":"Mycosis fungoides and S\u00e9zary syndrome: Australian clinical practice statement","volume":"62","author":"Bhabha","year":"2021","journal-title":"Austral J Dermatol"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0030","series-title":"Optimal cutaneous lymphoma care: A multidisciplinary, comprehensive approach","year":"2023"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0031","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/hematology.2021000263","article-title":"What factors guide treatment selection in mycosis fungoides and Sezary syndrome?","volume":"2021","author":"Kim","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0032","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0033","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British association of dermatologists and U.K. cutaneous lymphoma group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.679294","article-title":"A little experience goes a long way: Chlormethine\/mechlorethamine treatment duration as a function of clinician-level patient volume for mycosis fungoides cutaneous T-Cell lymphoma (MF-CTCL)-A retrospective cohort study","volume":"8","author":"Querfeld","year":"2021","journal-title":"Front Med"},{"issue":"8","key":"10.1016\/j.semradonc.2024.08.005_bib0035","article-title":"Annual facility treatment volume and patient survival for mycosis fungoides and s\u00e9zary syndrome","volume":"17","author":"Kann","year":"2017","journal-title":"Clin Lymph Myelom Leukem"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0036","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/bjd.13849","article-title":"Management of advanced cutaneous T-cell lymphoma: Role of the dermatologist in the multidisciplinary team","volume":"173","author":"Poligone","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0037","unstructured":"National Collaborating Centre for Cancer, Improving Outcomes for People with Skin Tumours including Melanoma - The Manual, 2006, Guidance on Cancer Services, National Institute for Health and Clinical Excellence, Available from: https:\/\/www.nice.org.uk\/guidance\/csg8\/evidence\/full-guideline-2006-pdf-2191950685"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0038","unstructured":"Optimal Care Pathways Australia: Cancer Council; 2023 Accessed March 12, 2024. Available from: https:\/\/www.cancer.org.au\/health-professionals\/optimal-cancer-care-pathways."},{"issue":"2","key":"10.1016\/j.semradonc.2024.08.005_bib0039","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JDN.0000000000000205","article-title":"Nursing best practice referral algorithm for the early detection of mycosis fungoides","volume":"8","author":"Lucas","year":"2016","journal-title":"J Dermatol Nurses' Assoc"},{"issue":"2","key":"10.1016\/j.semradonc.2024.08.005_bib0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1001\/jamadermatol.2022.5740","article-title":"Characteristics and outcomes for hospitalized patients with cutaneous T-Cell lymphoma","volume":"159","author":"Glinos","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.semradonc.2024.08.005_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000531979","article-title":"Causes of death in cutaneous T-Cell lymphoma patients","volume":"239","author":"Lebas","year":"2023","journal-title":"Dermatology"},{"issue":"13","key":"10.1016\/j.semradonc.2024.08.005_bib0042","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.2018888107","article-title":"Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma","volume":"134","author":"Lindahl","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0043","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/10428194.2022.2081324","article-title":"Mitigation strategies among cutaneous T-cell lymphoma patients with positive Staphylococcus aureus skin and soft tissue cultures have unclear impacts on the risk of subsequent bacteremia","volume":"64","author":"Allen","year":"2023","journal-title":"Leukem Lymphom"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 Update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"issue":"31","key":"10.1016\/j.semradonc.2024.08.005_bib0045","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.005_bib159","doi-asserted-by":"crossref","unstructured":"Campbell BA, Dobos G, Haider Z, et al: Improving disease-specific survival for patients with Sezary syndrome in the modern era of systemic therapies. Br J Haematol, 2024 (published online ahead of print 19 July 2024) . https:\/\/doi.org\/10.1111\/bjh.19647.","DOI":"10.1111\/bjh.19647"},{"issue":"21","key":"10.1016\/j.semradonc.2024.08.005_bib0046","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1182\/bloodadvances.2023011041","article-title":"International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies","volume":"7","author":"Campbell","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0047","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2018.01.076","article-title":"Blood classification and blood response criteria in mycosis fungoides and S\u00e9zary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force","volume":"93","author":"Scarisbrick","year":"2018","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0048","series-title":"International Classification of Diseases for Oncology","year":"2020"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0049","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.beha.2019.06.004","article-title":"Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and S\u00e9zary syndrome","volume":"32","author":"Martinez","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"9","key":"10.1016\/j.semradonc.2024.08.005_bib0050","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamadermatol.2016.1597","article-title":"Clinical staging and prognostic factors in folliculotropic mycosis fungoides","volume":"152","author":"van Santen","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.semradonc.2024.08.005_bib0051","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bjd.21738","article-title":"Large-cell transformation is an independent poor prognostic factor in S\u00e9zary syndrome: analysis of 117 cases","volume":"187","author":"Bontoux","year":"2022","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.semradonc.2024.08.005_bib0052","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood-2008-05-154609","article-title":"Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation","volume":"112","author":"Arulogun","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semradonc.2024.08.005_bib0053","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","article-title":"Prognostic factors in transformed mycosis fungoides: A retrospective analysis of 100 cases","volume":"119","author":"Benner","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semradonc.2024.08.005_bib0054","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bjd.21738","article-title":"Large-cell transformation is an independent poor prognostic factor in S\u00e9zary syndrome: Analysis of 117 cases","volume":"187","author":"Bontoux","year":"2022","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.semradonc.2024.08.005_bib0055","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.semradonc.2024.08.005_bib0056","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0057","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archderm.1996.03890250052009","article-title":"Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications","volume":"132","author":"Wasik","year":"1996","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0058","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1523-1747.2000.00830.x","article-title":"Detection of a peripheral blood T Cell clone is an independent prognostic marker in mycosis fungoides","volume":"114","author":"Fraser-Andrews","year":"2000","journal-title":"J Investigat Dermatol"},{"issue":"9","key":"10.1016\/j.semradonc.2024.08.005_bib0059","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/(SICI)1097-0142(19960501)77:9<1912::AID-CNCR23>3.0.CO;2-1","article-title":"Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T-cell lymphoma treated with total skin electron beam radiation therapy","volume":"77","author":"Quiros","year":"1996","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.semradonc.2024.08.005_bib0060","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: Clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0061","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1046\/j.0022-202x.2001.01476.x","article-title":"Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas","volume":"117","author":"Beylot-Barry","year":"2001","journal-title":"J Investigat Dermatol"},{"issue":"13","key":"10.1016\/j.semradonc.2024.08.005_bib0062","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.ejca.2013.04.018","article-title":"A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome","volume":"49","author":"Benton","year":"2013","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"32","key":"10.1016\/j.semradonc.2024.08.005_bib0063","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and s\u00e9zary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2024.08.005_bib0064","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.clon.2019.07.018","article-title":"Cutaneous lymphomas","volume":"31","author":"Specht","year":"2019","journal-title":"Cli Oncol"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0065","series-title":"Primary Cutaneous Lymphomas Version 1.2024","year":"2024"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0066","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British association of dermatologists and U.K. cutaneous lymphoma group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0067","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: Field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.semradonc.2024.08.005_bib0068","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.3390\/cancers12082311","article-title":"Time to next treatment as a meaningful endpoint for trials of primary cutaneous lymphoma","volume":"12","author":"Campbell","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.semradonc.2024.08.005_bib0069","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/0360-3016(83)90321-8","article-title":"Palliative radiation treatment of cutaneous mycosis fungoides: A dose response","volume":"9","author":"Cotter","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0070","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-Cell lymphomas","volume":"74","author":"Neelis","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2024.08.005_bib0071","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/j.prro.2022.10.004","article-title":"Optimizing palliative focal radiation therapy dose in cutaneous T-Cell lymphoma: How low can you go?","volume":"13","author":"Patel","year":"2023","journal-title":"Pract Radiat Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2024.08.005_bib0072","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2174\/1573405617666210202114336","article-title":"Evaluating 3D-printed bolus compared to conventional bolus types used in external beam radiation therapy","volume":"17","author":"McCallum","year":"2021","journal-title":"Curr Med Imag"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0073","article-title":"Extensive cutaneous T-cell lymphoma of the feet treated with high-dose-rate brachytherapy and external beam radiation","volume":"2018","author":"Tao","year":"2018","journal-title":"Case Rep Dermatol Med"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0074","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaad.2012.12.975","article-title":"Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma","volume":"69","author":"DeSimone","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0075","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ijrobp.2012.05.034","article-title":"Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-Cell lymphoma","volume":"85","author":"Thomas","year":"2013","journal-title":"Int J Radiat Oncol Biolo Phys"},{"issue":"supplement 1","key":"10.1016\/j.semradonc.2024.08.005_bib0076","doi-asserted-by":"crossref","first-page":"S1131","DOI":"10.1016\/S0167-8140(24)00959-9","article-title":"Mycosis fungoides with large cell transformation: Radiotherapy dose response and patient outcomes","volume":"194","author":"Johnstone","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2024.08.005_bib160","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0360-3016(98)00218-1","article-title":"Radiotherapy for unilesional mycosis fungoides","volume":"42","author":"Micaily","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.08.005_bib161","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0360-3016(97)00553-1","article-title":"Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (Mycosis Fungoides)","volume":"40","author":"Wilson","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2024.08.005_bib0077","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaad.2014.10.014","article-title":"Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials","volume":"72","author":"Hoppe","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.semradonc.2024.08.005_bib0078","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/cancers11111758","article-title":"Lack of durable remission with conventional-dose total skin electron therapy for the management of sezary syndrome and multiply relapsed mycosis fungoides","volume":"11","author":"Campbell","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0079","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00066-019-01517-7","article-title":"Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome","volume":"196","author":"Elsayad","year":"2020","journal-title":"Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft"},{"issue":"9-10","key":"10.1016\/j.semradonc.2024.08.005_bib0080","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0360-3016(77)90182-1","article-title":"The rationale for curative radiotherapy in mycosis fungoides","volume":"2","author":"Hoppe","year":"1977","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.semradonc.2024.08.005_bib0081","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3109\/0284186X.2011.585999","article-title":"Total skin electron beam therapy for cutaneous T-cell lymphoma: A nationwide cohort study from Denmark","volume":"50","author":"Lindahl","year":"2011","journal-title":"Acta Oncologica"},{"issue":"5","key":"10.1016\/j.semradonc.2024.08.005_bib0082","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0360-3016(98)00517-3","article-title":"Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides","volume":"43","author":"Chinn","year":"1999","journal-title":"Int J Radiat Oncol Bio Phys"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0083","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0360-3016(94)90103-1","article-title":"Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 GY","volume":"28","author":"Jones","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.semradonc.2024.08.005_bib0084","first-page":"1985","article-title":"Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome)","volume":"85","author":"Jones","year":"1999","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.semradonc.2024.08.005_bib0085","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0360-3016(97)00127-2","article-title":"Total skin electron beam therapy followed by adjuvant psoralen\/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)","volume":"38","author":"Quir\u00f3s","year":"1997","journal-title":"Int J Radiat Oncol Bio Phys"},{"issue":"10","key":"10.1016\/j.semradonc.2024.08.005_bib0086","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clon.2018.06.006","article-title":"Total skin electron irradiation and sequential malignancies in mycosis fungoides patients: Longitudinal study","volume":"30","author":"Lutsyk","year":"2018","journal-title":"Clin Oncol"},{"issue":"25","key":"10.1016\/j.semradonc.2024.08.005_bib0087","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2015-12-611830","article-title":"How I treat mycosis fungoides and S\u00e9zary syndrome","volume":"127","author":"Whittaker","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0088","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijrobp.2015.01.047","article-title":"Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: An open clinical study and pooled data analysis","volume":"92","author":"Kamstrup","year":"2015","journal-title":"Int J Radiat Oncol Bio Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2024.08.005_bib0089","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2133.2011.10670.x","article-title":"Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: An open-label prospective phase II study","volume":"166","author":"Kamstrup","year":"2012","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0090","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.ijrobp.2007.11.039","article-title":"A prospective, open-label study of low-dose total skin electron beam therapy in mycosis fungoides","volume":"71","author":"Kamstrup","year":"2008","journal-title":"Int J Radiat Oncol Bio Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0091","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaad.2020.01.046","article-title":"A prospective cohort study of condensed low-dose total skin electron beam therapy for mycosis fungoides: Reduction of disease burden and improvement in quality of life","volume":"83","author":"Song","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0092","doi-asserted-by":"crossref","first-page":"e13478","DOI":"10.1111\/dth.13478","article-title":"Low dose total skin electron beam therapy for the management of T cell cutaneous lymphomas","volume":"33","author":"Georgakopoulos","year":"2020","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0093","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijrobp.2023.02.052","article-title":"Ultrahypofractionated low-dose total skin electron beam in advanced-stage mycosis fungoides and s\u00e9zary syndrome","volume":"117","author":"Elsayad","year":"2023","journal-title":"Int J Radiat Oncol Bio Phys"},{"issue":"21","key":"10.1016\/j.semradonc.2024.08.005_bib0094","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood.2020006028","article-title":"ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic","volume":"135","author":"Yahalom","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0158","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ijrobp.2017.05.052","article-title":"The Results of low-dose total skin electron beam radiation therapy (TSEB) in patients with mycosis fungoides from the UK Cutaneous Lymphoma Group","volume":"99","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.semradonc.2024.08.005_bib0095","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/annonc\/mdx352","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: A multicenter retrospective follow-up study from the cutaneous lymphoma international consortium","volume":"28","author":"Quaglino","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2024.08.005_bib0096","article-title":"Maintenance therapy for cutaneous T-cell lymphoma after total skin electron irradiation: Evidence for improved overall survival with ultraviolet therapy","volume":"20","author":"Kudelka","year":"2020","journal-title":"Clin Lymph Myelom Leukem"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0097","first-page":"279","article-title":"Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphoma","volume":"20","author":"Elsayad","year":"2022","journal-title":"JDDG: J der Deutschen Dermatologischen Gesellschaft"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0098","article-title":"Low-dose total skin electron beam therapy combined with mogamulizumab for refractory mycosis fungoides and s\u00e9zary syndrome","volume":"6","author":"Fong","year":"2021","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0099","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamadermatol.2020.3958","article-title":"Low-dose total skin electron beam therapy as part of a multimodality regimen for treatment of s\u00e9zary syndrome: Clinical, immunologic, and molecular analysis","volume":"157","author":"Durgin","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"1 Pt 1","key":"10.1016\/j.semradonc.2024.08.005_bib0100","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1067\/mjd.2000.105510","article-title":"Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides","volume":"43","author":"Wilson","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"26","key":"10.1016\/j.semradonc.2024.08.005_bib0101","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"New Eng J Med"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0102","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/bjd.12386","article-title":"Mycosis fungoides: the addition of concurrent and adjuvant interferon to total skin electron beam therapy","volume":"169","author":"Wagner","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0103","unstructured":"Kim Y. NCT04256018. In: Campbell B, (ed). email ed2023."},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/j.adro.2020.11.014","article-title":"Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and S\u00e9zary Syndrome","volume":"6","author":"Fong","year":"2021","journal-title":"Advances in Radiation Oncology"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0105","unstructured":"EORTC-1820-CLTG: EORTC; Accessed February 26, 2024. Available from: https:\/\/www.eortc.org\/research_field\/clinical-detail\/1820\/."},{"key":"10.1016\/j.semradonc.2024.08.005_bib0106","unstructured":"Dabaja B. NCT05357794. In: Campbell B, (ed). email ed2023."},{"key":"10.1016\/j.semradonc.2024.08.005_bib0107","unstructured":"Imber B. ClinicalTrials.gov ID NCT05296304 In: Campbell B, (ed), email ed2024."},{"issue":"10392","key":"10.1016\/j.semradonc.2024.08.005_bib0108","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(23)00329-X","article-title":"Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): A propensity score matched controlled prospective study","volume":"401","author":"de Masson","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.semradonc.2024.08.005_bib0109","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s41409-020-01197-3","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and S\u00e9zary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"56","author":"Domingo-Domenech","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0110","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbmt.2019.08.019","article-title":"Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T Cell lymphoma: Results of a systematic review and meta-analysis","volume":"26","author":"Iqbal","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.semradonc.2024.08.005_bib0111","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.3390\/cancers12102856","article-title":"Allogeneic hematopoietic stem cell transplantation in cutaneous T-Cell lymphomas","volume":"12","author":"Dumont","year":"2020","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.semradonc.2024.08.005_bib0112","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.semradonc.2024.08.005_bib0113","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/annonc\/mdv473","article-title":"Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: Updated results from a single institution","volume":"26","author":"Hosing","year":"2015","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.semradonc.2024.08.005_bib0114","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1182\/bloodadvances.2020001627","article-title":"Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma","volume":"4","author":"Weng","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.semradonc.2024.08.005_bib0115","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41409-024-02236-z","article-title":"Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for mycosis fungoides and sezary syndrome","volume":"59","author":"Morris","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0116","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1067\/mjd.2002.123482","article-title":"Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group","volume":"47","author":"Jones","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0117","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5114\/pdia.2013.33379","article-title":"Total skin electron irradiation techniques: a review","volume":"30","author":"Piotrowski","year":"2013","journal-title":"Postepy dermatologii i alergologii"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0118","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1396-0296.2003.01647.x","article-title":"Mycosis fungoides: Radiation therapy","volume":"16","author":"Hoppe","year":"2003","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0119","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jmir.2022.08.006","article-title":"Computational dose visualization & comparison in total skin electron treatment suggests superior coverage by the rotational versus the Stanford technique","volume":"53","author":"Miao","year":"2022","journal-title":"J Med Imag Radiat Sci"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1507-1367(06)71047-1","article-title":"The rotary dual technique for total skin irradiation in the treatment of mycosis fungoides: A description of the applied method","volume":"11","author":"Piotrowski","year":"2006","journal-title":"Rep Pract Oncol and Radiother"},{"issue":"11","key":"10.1016\/j.semradonc.2024.08.005_bib0121","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1080\/1042819021000016177","article-title":"Total skin electron irradiation in mycosis fungoides: Comparison between a modified christie hospital translational technique and the stanford technique","volume":"43","author":"Anacak","year":"2002","journal-title":"Leukem Lymph"},{"issue":"616","key":"10.1016\/j.semradonc.2024.08.005_bib0122","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1259\/0007-1285-52-616-302","article-title":"Whole body electron therapy in mycosis fungoides: A successful translational technique achieved by modification of an established linear accelerator","volume":"52","author":"Williams","year":"1979","journal-title":"Br J Radiol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0123","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1120\/jacmp.v9i4.2793","article-title":"Rotational total skin electron irradiation with a linear accelerator","volume":"9","author":"Reynard","year":"2008","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0124","series-title":"Total skin electron therapy: Technique and dosimetry","year":"1987"},{"issue":"5","key":"10.1016\/j.semradonc.2024.08.005_bib0125","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.3390\/ijms24054492","article-title":"Total skin treatment with helical arc radiotherapy","volume":"24","author":"Nien","year":"2023","journal-title":"Int J Molecul Sci"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0126","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.prro.2020.11.007","article-title":"Helical skin radiation therapy including total skin radiation therapy using tomotherapy for primary cutaneous lymphoma with bone marrow suppression as a related adverse event","volume":"11","author":"Kitaguchi","year":"2021","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0127","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13014-018-1100-4","article-title":"Light and shadows of a new technique: Is photon total-skin irradiation using helical IMRT feasible, less complex and as toxic as the electrons one?","volume":"13","author":"Buglione","year":"2018","journal-title":"Radiat Oncol (London, England)"},{"issue":"7","key":"10.1016\/j.semradonc.2024.08.005_bib0128","first-page":"574","article-title":"Evens AM. Primary cutaneous and systemic anaplastic large cell lymphoma: Clinicopathologic aspects and therapeutic options","volume":"24","author":"Querfeld","year":"2010","journal-title":"Oncology (Williston Park, NY)"},{"issue":"5","key":"10.1016\/j.semradonc.2024.08.005_bib0129","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1684\/ejd.2017.3083","article-title":"18)F-fluorodeoxyglucose-positron emission tomography is more sensitive than computed tomography in initial staging of patients with an anaplastic T-cell lymphoma first presenting in the skin","volume":"27","author":"Ram-Wolff","year":"2017","journal-title":"Eur J Dermatol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jaad.2020.04.073","article-title":"The importance of differentiating between mycosis fungoides with CD30-positive large cell transformation and mycosis fungoides with coexistent primary cutaneous anaplastic large cell lymphoma","volume":"84","author":"Gao","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.semradonc.2024.08.005_bib0131","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: A report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semradonc.2024.08.005_bib0132","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/bjh.14404","article-title":"Outcome of primary cutaneous anaplastic large cell lymphoma: A 20-year British Columbia Cancer Agency experience","volume":"176","author":"Hapgood","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.semradonc.2024.08.005_bib0133","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.ijrobp.2016.03.023","article-title":"Radiation Therapy for primary cutaneous anaplastic large cell lymphoma: An International Lymphoma Radiation Oncology Group multi-institutional experience","volume":"95","author":"Million","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2024.08.005_bib0134","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ijrobp.2017.08.010","article-title":"Recommendations for the optimal radiation dose in patients with primary cutaneous anaplastic large cell lymphoma: A Report of the Dutch Cutaneous Lymphoma Group","volume":"99","author":"Melchers","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0135","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/ijd.14754","article-title":"Radiotherapy of primary cutaneous anaplastic large cell lymphoma: Our experience in 30 cases","volume":"59","author":"Piccinno","year":"2020","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0136","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/bjd.16501","article-title":"Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: Report of the Dutch Cutaneous Lymphoma Group","volume":"179","author":"Melchers","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0137","article-title":"Single-fraction radiotherapy for CD30(+) lymphoproliferative disorders","volume":"2015","author":"Gentile","year":"2015","journal-title":"Bio Med Res Int"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0138","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.adro.2017.06.004","article-title":"Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma","volume":"2","author":"Smith","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0139","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.11.019","article-title":"Excellent treatment outcomes from low dose radiation therapy for primary cutaneous CD4+ small\/medium T-Cell lymphoproliferative disorder","volume":"178","author":"Ward","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/aol-21-41","article-title":"The gamma delta lymphomas: An Australian multi-centre case series","volume":"6","author":"Harrop","year":"2022","journal-title":"Ann Lymph"},{"issue":"5","key":"10.1016\/j.semradonc.2024.08.005_bib0141","doi-asserted-by":"crossref","first-page":"394","DOI":"10.5301\/tj.5000606","article-title":"Primary cutaneous non-Hodgkin lymphoma: Results of a retrospective analysis in the light of the recent ILROG guidelines","volume":"104","author":"Pedretti","year":"2018","journal-title":"Tumori J"},{"issue":"7","key":"10.1016\/j.semradonc.2024.08.005_bib0142","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jdcr.2019.05.002","article-title":"Radiation therapy for primary cutaneous \u03b3\u03b4 T-cell lymphoma: Case report and literature review","volume":"5","author":"Kelsey","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.semradonc.2024.08.005_bib0143","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.prro.2019.02.016","article-title":"Volumetric modulated Arc therapy and 3-dimensional printed bolus in the treatment of refractory primary cutaneous gamma delta lymphoma of the bilateral legs","volume":"9","author":"Obeid","year":"2019","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2024.08.005_bib0144","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/modpathol.2016.240","article-title":"Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: Reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas","volume":"30","author":"Guitart","year":"2017","journal-title":"Modern Pathol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0145","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/PGP.0000000000000648","article-title":"Vulvar primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-Cell lymphoma","volume":"40","author":"Morse","year":"2021","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.08.005_bib0146","doi-asserted-by":"crossref","first-page":"253","DOI":"10.21873\/anticanres.13105","article-title":"Cutaneous T-cell lymphoma: Trends in radiation doses and patterns of care 2004-2015","volume":"39","author":"Miccio","year":"2019","journal-title":"Anticanc Res"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0147","series-title":"Review of Optimal Radiotherapy Utilisation Rates. Prepared for Department of Health and Aging","author":"Barton MJ","year":"2013"},{"issue":"S3","key":"10.1016\/j.semradonc.2024.08.005_bib0148","first-page":"105","article-title":"Poster Abstracts; 328 Lower radiotherapy utilisation in patients with cutaneous T-cell lymphomas (CTCL) living in highly accessible areas","volume":"19","author":"Campbell","year":"2023","journal-title":"Asia-Pacific J Clin Oncol"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0149","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/1360740","article-title":"Suggested guidelines for the treatment of mycosis fungoides in countries with limited resources","volume":"2023","author":"Ibrahim","year":"2023","journal-title":"Dermatol Res Pract"},{"issue":"11","key":"10.1016\/j.semradonc.2024.08.005_bib0150","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013059","article-title":"Are differences in travel time or distance to healthcare for adults in global north countries associated with an impact on health outcomes? A systematic review","volume":"6","author":"Kelly","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0151","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-4-8","article-title":"Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: New insights for an accurate description","volume":"9","author":"D\u2019Agostino","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0152","series-title":"Treatment Centers and Clinical Trials","year":"2024"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0153","unstructured":"OECD. Population (indicator): Organisation for economic co-operation and development; 2024 Accessed February 29, 2024. Available from: https:\/\/data.oecd.org\/pop\/population.htm."},{"key":"10.1016\/j.semradonc.2024.08.005_bib0154","unstructured":"Specht L. In: Campbell B, (ed). email ed2024."},{"issue":"3","key":"10.1016\/j.semradonc.2024.08.005_bib0155","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.prro.2023.12.010","article-title":"Practical implications of the American Society for radiation oncology radiation oncology case rate program proposal for radiation oncologists","volume":"14","author":"Yu","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.semradonc.2024.08.005_bib0156","unstructured":"American Society for Radiation Oncology, The Radiation Oncology Case Rate (ROCR) Report (ed June 2023). VA, USA, American Society for Radiation Oncology, 2024. Available from: https:\/\/www.astro.org\/ASTRO\/media\/ASTRO\/Advocacy\/PDFs\/ROCRReport.pdf."},{"key":"10.1016\/j.semradonc.2024.08.005_bib0157","series-title":"Radiation Oncology Case Rate Program (ROCR) Arlington","year":"2023"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429624000699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429624000699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T13:59:53Z","timestamp":1734011993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429624000699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":161,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1053429624000699"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2024.08.005","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking Down the Barriers for Patients With Cutaneous T-Cell Lymphoma: Current Controversies and Challenges for Radiation Oncologists in 2024","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2024.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}